To view enhanced content for this article go to http://www.medengine.com/Redeem/C31DF0607ED36CA2.
Longer medication persistence in type 2 diabetes (T2D) is associated with improved glycaemic control. It is not clear which oral therapies have the best persistence. The objective of this study was to compare medication persistence across different oral therapies in people with T2D.
We performed a retrospective cohort analysis using a primary-care-based population, the Royal College of General Practitioners Research and Surveillance Centre cohort. We identified new prescriptions for oral diabetes medication in people with type 2 diabetes between January 1, 2004 and July 31, 2015. We compared median persistence across each class. We also compared non-persistence (defined as a prescription gap of ≥ 90 days) between classes, adjusting for confounders, using Cox regression. Confounders included: age, gender, ethnicity, socioeconomic status, alcohol use, smoking status, glycaemic control, diabetes duration, diabetes complications, comorbidities, and number of previous and concurrent diabetes medications.
We identified 60,327 adults with T2D. The majority 42,810 (70.9%) of those had one or more oral medications prescribed; we measured persistence in those patients (who were prescribed 55,728 oral medications in total). Metformin had the longest median persistence (3.04 years; 95% CI 2.94–3.12). The adjusted hazard ratios for non-persistence compared with metformin were: sulfonylureas HR 1.20 (1.16–1.24), DPP-4 inhibitors HR 1.43 (1.38–1.49), thiazolidinediones HR 1.71 (95% CI 1.64–1.77), SGLT2 inhibitors HR 1.04 (0.93–1.17), meglitinides HR 2.25 (1.97–2.58), and alpha-glucosidase inhibitors HR 2.45 (1.98–3.02). The analysis of SGLT2 inhibitors was limited by the short duration of follow-up for this new class. Other factors associated with reduced medication persistence were female gender, younger age, and non-white ethnicity.
Persistence is strongly influenced by medication class and should be considered when initiating treatments.
World Health Organization. Adherence to long-term therapies: evidence for action. Geneva: WHO; 2003.
Trogdon JG, et al. Peer reviewed: costs of chronic diseases at the state level: the chronic disease cost calculator. Prev Chron Dis. 2015;12:150131.
Al-Majed HT, et al. Adherence of type-2 diabetic patients to treatment. Kuwait Med J. 2014;46(3):225–32.
Rozenfeld Y, et al. Oral antidiabetic medication adherence and glycemic control in managed care. Am J Manag Care. 2008;14(2):71–5. PubMed
Wu CH, et al. The eight-item Morisky Medication Adherence Scale (MMAS-8) score was associated with glycaemic control in diabetes patients. Hypertension. 2014;64(Suppl 1):A558.
Heaton PC, Tundia NL, Luder HR. US emergency departments visits resulting from poor medication adherence: 2005–07. J Am Pharm Assoc. 2003;53(5):513–9. CrossRef
Zhu VJ, et al. Oral hypoglycemic agent adherence and hospitalization among patients with type 2 diabetes: a call for enhanced guidelines. Pharmacoepidemiol Drug Saf. 2012;21(S3):29.
Lee WC, et al. Prevalence and economic consequences of medication adherence in diabetes: a systematic literature review. Manag Care Interface. 2006;19(7):31–41. PubMed
Macewan JP, et al. Penny-wise, pound-foolish: association between medication adherence, out-of-pocket expenses, and health care costs in medicare patients with type 2 diabetes. Diabetes. 2015;64(S1):A69.
Nasseh K, et al. Cost of medication nonadherence associated with diabetes, hypertension, and dyslipidemia. Am J Pharm Benefits. 2012;4(2):e41–7.
Hong S, et al. Compliance with anti-diabetic medication improves cardiovascular outcomes in patients with type 2 diabetes. Diabetes. 2013;62(S1):A372.
Wu C-S. Antihyperglycemic adherence and risk of stroke among type II diabetes mellitus: a population-based retrospective cohort study. Dissertation. University of South Carolina: Columbia; 2012.
Office for National Statistics. Ethnicity. 2015. https://www.ons.gov.uk/peoplepopulationandcommunity/culturalidentity/ethnicity. Accessed 28 Dec 2017.
Fisher L, et al. Emotional distress is linked to medication adherence in type 2 diabetes. Diabetes. 2009;58:A478.
Leblond J, et al. Predictors of nonpersistence with thiazolidinediones in patients with type 2 diabetes. Can J Diabetes. 2005;29(2):95–102.
Gwadry-Sridhar F, et al. Influence of previous medication compliance on future compliance in patients with type 2 diabetes. Diabetes. 2010;59:A346.
McGovern A, et al. A comparison of adherence and persistence by medication class in type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2017. https://doi.org/10.1111/dom.13160.
Gwadry-Sridhar F, et al. Understanding predictors of compliance in fixed-dose combination vs loose-dose combination therapy for treatment of type 2 diabetes. Diabetes. 2010;59:A346.
Hessler DM, et al. Low patient trust in their primary care provider predicts medication nonadherence 12 months later. Diabetes. 2014;63:A194.
- A Class Comparison of Medication Persistence in People with Type 2 Diabetes: A Retrospective Observational Study
Simon de Lusignan
- Springer Healthcare
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
e.Med Kampagnen-Visual, Mail Icon II